# PTC Therapeutics, Inc. (PTCT) FY2026 Q3 Balance Sheet

- Company: PTC Therapeutics, Inc. (PTCT)
- Period: As of 2026-09-30
- Filing: Q3 FY2026 10-Q, filed 2026-10-29, accession number 0001104659-26-120223
- Page: https://plicit.ai/financials/ptct/fy2026-q3-balance-sheet
- Chart image: https://plicit.ai/charts/ptct-fy2026-q3-balance-sheet-sankey.png

## Chart details

Balance sheet as of 2026-09-30. The chart shows assets, liabilities and equity at that date.

- **Assets**: 3,207,715,000 US dollars
- **Current assets**: 2,537,784,000 US dollars
- **Non-current assets**: 669,931,000 US dollars
- **Liabilities**: 3,398,924,000 US dollars
- **Current liabilities**: 776,076,000 US dollars
- **Non-current liabilities**: 2,622,848,000 US dollars
- **Shareholders' deficit**: negative 191,209,000 US dollars
- **Marketable securities**: 1,619,024,000 US dollars
- **Cash and cash equivalents**: 508,894,000 US dollars
- **Trade and royalty receivables, net**: 238,069,000 US dollars
- **Inventory, net**: 109,332,000 US dollars
- **Prepaid expenses and other current assets**: 62,465,000 US dollars
- **Intangible assets, net**: 443,686,000 US dollars
- **Goodwill**: 82,341,000 US dollars
- **Operating lease ROU assets**: 72,953,000 US dollars
- **Fixed assets, net**: 49,325,000 US dollars
- **Deposits and other assets**: 21,626,000 US dollars
- **Accounts payable and accrued expenses**: 440,811,000 US dollars
- **Liability for sale of future royalties- current**: 319,078,000 US dollars
- **Operating lease liabilities- current**: 11,212,000 US dollars
- **Finance lease liabilities- current**: 3,000,000 US dollars
- **Deferred revenue**: 1,975,000 US dollars
- **Liability for sale of future royalties- noncurrent**: 1,986,525,000 US dollars
- **Long-term debt**: 536,268,000 US dollars
- **Operating lease liabilities- noncurrent**: 85,554,000 US dollars
- **Other long-term liabilities**: 14,501,000 US dollars
- **Additional paid-in capital**: 2,741,391,000 US dollars
- **Accumulated other comprehensive income**: 2,553,000 US dollars
- **Common stock, $0.001 par value. Authorized 250,000,000 shares; issued and outstanding 83,535,767 shares at September 30, 2026. Authorized 250,000,000 shares; issued and outstanding 81,474,366 shares at December 31, 2025.**: 82,000 US dollars
- **Accumulated deficit**: negative 2,935,235,000 US dollars

### Chart connections

- Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
- Treasury shares and other negative equity contributions reduce equity.
